NanoString Technologies, Inc. provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and Pan Cancer and 360 gene expression, protein immune profiling, neuropathology and neuro-inflammation gene expression, autoimmune disease gene expression, nCounter Vantage 3D, miRNA expression, cancer copy number variation, and other gene expression panels. Further, the company offers nCounter-based reagents that allow users to design customized assays; Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and nCounter Dx Analysis System and Prosigna molecular diagnostic test kits. It has collaboration with Celgene Corporation; Merck & Co., Inc.; Medivation, Inc.; and Astellas Pharma, Inc., as well as the Cancer Therapy Evaluation Program of the National Cancer Institute. The company was founded in 2003 and is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NSTG
Previous Symbol
CUSIPN/A
Phone206-378-6266
Debt
Debt-to-Equity Ratio0.96
Current Ratio3.62
Quick Ratio3.22
Price-To-Earnings
Trailing P/E Ratio-9.27
Forward P/E Ratio-6.56
P/E GrowthN/A
Sales & Book Value
Annual Sales$114.90 million
Price / Sales4.57
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.58 per share
Price / Book10.79
Profitability
EPS (Most Recent Fiscal Year)($1.84)
Net Income$-43,560,000.00
Net Margins-58.11%
Return on Equity-206.80%
Return on Assets-50.85%
Miscellaneous
Employees467
Outstanding Shares30,830,000
Market Cap$534 million
OptionableOptionable
NanoString Technologies (NASDAQ:NSTG) Frequently Asked Questions
What is NanoString Technologies' stock symbol?
NanoString Technologies trades on the NASDAQ under the ticker symbol "NSTG."
How were NanoString Technologies' earnings last quarter?
NanoString Technologies Inc (NASDAQ:NSTG) released its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.57) by $0.01. The biotechnology company earned $28.62 million during the quarter, compared to analysts' expectations of $25.90 million. NanoString Technologies had a negative return on equity of 206.80% and a negative net margin of 58.11%. View NanoString Technologies' Earnings History.
When is NanoString Technologies' next earnings date?
What guidance has NanoString Technologies issued on next quarter's earnings?
NanoString Technologies updated its FY 2018 earnings guidance on Thursday, November, 8th. The company provided earnings per share (EPS) guidance of $-2.5--2.6 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $-2.54. The company issued revenue guidance of $104-106 million, compared to the consensus revenue estimate of $105.59 million.
What price target have analysts set for NSTG?
4 Wall Street analysts have issued twelve-month price targets for NanoString Technologies' stock. Their predictions range from $18.00 to $23.00. On average, they expect NanoString Technologies' share price to reach $19.75 in the next twelve months. This suggests a possible upside of 15.8% from the stock's current price. View Analyst Price Targets for NanoString Technologies.
What is the consensus analysts' recommendation for NanoString Technologies?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NanoString Technologies in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NanoString Technologies.
Has NanoString Technologies been receiving favorable news coverage?
News stories about NSTG stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NanoString Technologies earned a news sentiment score of -1.3 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.
Who are some of NanoString Technologies' key competitors?
Some companies that are related to NanoString Technologies include Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Spark Therapeutics (ONCE), Rubius Therapeutics (RUBY), Editas Medicine (EDIT), Orchard Therapeutics (ORTX), Autolus Therapeutics (AUTL), Iovance Biotherapeutics (IOVA), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE), Audentes Therapeutics (BOLD) and BioCryst Pharmaceuticals (BCRX).
Who are NanoString Technologies' key executives?
NanoString Technologies' management team includes the folowing people:
- Mr. R. Bradley Gray, CEO, Pres & Director (Age 41)
- Mr. J. Chad Brown, Sr. VP of Sales & Marketing (Age 60)
- Dr. Joseph M. Beechem, Sr. VP of R&D (Age 60)
- Mr. K. Thomas Bailey, CFO & Treasurer (Age 49)
- Dr. Mary Tedd Allen, Sr. VP of Operations (Age 55)
Who are NanoString Technologies' major shareholders?
NanoString Technologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (11.53%), BlackRock Inc. (7.42%), Morgan Stanley (5.86%), Neuberger Berman Group LLC (4.00%), Vanguard Group Inc. (3.97%) and Vanguard Group Inc (3.97%). Company insiders that own NanoString Technologies stock include David W Ghesquiere, Mary Tedd Allen, Nicholas Galakatos, R Bradley Gray and William Young. View Institutional Ownership Trends for NanoString Technologies.
Which institutional investors are selling NanoString Technologies stock?
NSTG stock was sold by a variety of institutional investors in the last quarter, including Algert Global LLC, Bridgeway Capital Management Inc., Alambic Investment Management L.P. and GSA Capital Partners LLP. Company insiders that have sold NanoString Technologies company stock in the last year include Mary Tedd Allen and Nicholas Galakatos. View Insider Buying and Selling for NanoString Technologies.
Which institutional investors are buying NanoString Technologies stock?
NSTG stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Point72 Asset Management L.P., BlackRock Inc., Morgan Stanley, Neuberger Berman Group LLC, Marshall Wace LLP, Vanguard Group Inc and Vanguard Group Inc.. View Insider Buying and Selling for NanoString Technologies.
How do I buy shares of NanoString Technologies?
Shares of NSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NanoString Technologies' stock price today?
One share of NSTG stock can currently be purchased for approximately $17.05.
How big of a company is NanoString Technologies?
NanoString Technologies has a market capitalization of $534 million and generates $114.90 million in revenue each year. The biotechnology company earns $-43,560,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. NanoString Technologies employs 467 workers across the globe.
What is NanoString Technologies' official website?
How can I contact NanoString Technologies?
NanoString Technologies' mailing address is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. The biotechnology company can be reached via phone at 206-378-6266 or via email at [email protected]
MarketBeat Community Rating for NanoString Technologies (NASDAQ NSTG)
MarketBeat's community ratings are surveys of what our community members think about NanoString Technologies and other stocks. Vote "Outperform" if you believe NSTG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NSTG will underperform the S&P 500 over the long term. You may vote once every thirty days.
